Vir Biotechnology, Inc. (VIR)
9.97
-0.50
(-4.78%)
USD |
NASDAQ |
Oct 16, 13:27
Vir Biotechnology SG&A Expense (TTM) : 99.38M for June 30, 2026
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 99.38M |
| March 31, 2026 | 91.47M |
| December 31, 2025 | 92.07M |
| September 30, 2025 | 95.16M |
| June 30, 2025 | 98.67M |
| March 31, 2025 | 106.65M |
| December 31, 2024 | 118.98M |
| September 30, 2024 | 135.37M |
| June 30, 2024 | 150.71M |
| March 31, 2024 | 167.54M |
| December 31, 2023 | 178.05M |
| September 30, 2023 | 173.70M |
| June 30, 2023 | 175.80M |
| March 31, 2023 | 170.28M |
| December 31, 2022 | 161.76M |
| September 30, 2022 | 178.80M |
| Date | Value |
|---|---|
| June 30, 2022 | 186.12M |
| March 31, 2022 | 173.31M |
| December 31, 2021 | 160.79M |
| September 30, 2021 | 128.06M |
| June 30, 2021 | 96.42M |
| March 31, 2021 | 84.03M |
| December 31, 2020 | 70.94M |
| September 30, 2020 | 59.70M |
| June 30, 2020 | 50.06M |
| March 31, 2020 | 41.69M |
| December 31, 2019 | 37.60M |
| September 30, 2019 | 33.74M |
| June 30, 2019 | 31.91M |
| March 31, 2019 | 23.90M |
| December 31, 2018 | 15.34M |
| September 30, 2018 | 7.394M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Moderna, Inc. | 965.00M |
| Vaxcyte, Inc. | 132.67M |
| Caribou Biosciences, Inc. | 33.74M |
| Arrowhead Pharmaceuticals, Inc. | 172.57M |
| Oncolytics Biotech, Inc. | 16.62M |